Pfizer along with other international no-borders monopolies is a goldmine for investors demanding that every citizen gets the mind-controlling vaccine jab. Drugs giant Pfizer has been fined a record £84.2m by the UK’s competition watchdog for overcharging the NHS for an anti-epilepsy drug. 

The Competition and Markets Authority (CMA) also fined distributor Flynn Pharma £5.2m for the 2,600% overnight price increase for the drug in 2012. NHS spending on the capsules, used by 48,000 UK patients, rose from £2m a year in 2012 to about £50m in 2013. said it would appeal against the decision.

UK prices for the drug were many times higher than in Europe, the CMA said.

Philip Marsden of the CMA said: ‘The companies deliberately exploited the opportunity offered by de-branding to hike up the price for a drug which is relied upon by many thousands of patients.

‘These extraordinary price rises have cost the NHS and the taxpayer tens of millions of pounds.’

Before 2012, Pfizer manufactured and distributed the drug, which was branded Epanutin. Pfizer then sold the UK rights to distribute the phenytoin sodium capsules to Flynn Pharma, which de-branded the drug. That allowed the firms to charge more for the drug because it was no longer subject to a pricing scheme agreed between the NHS and the drugs industry, the CMA said.

However, Pfizer said the drug was a loss-making product, and that the deal with Flynn ‘represented an opportunity to secure an ongoing supply of an important medicine for patients with epilepsy’.

The firms have between 30 days and four months to reduce the price to a level acceptable to the CMA, and two months to appeal against the CMA decision to the Competition Tribunal. Bizarrey, the fine will go to the Treasury rather than the NHS directly, although the health service could try to seek damages.

Drugs industry body the Association of the British Pharmaceutical Industry said it ‘does not in any way support or condone the practice of ‘price hikes’ to generic medicines. Whilst we can’t comment on individual companies and an appeal being made, it’s appropriate that the complexities of this case are considered through the on-going legal process,’ the organisation said.

Europe Renaissance position is that rules should be in place that prohibits legislators and owners of mainstream media from profiteering from firms acquiring contracts via parliament, its ministries or its appointed buying organisations. Sadly, turkeys don’t vote for Christmas. Source

FOLLOW MY BLOG AND PLEASE SHARE MY STORIES.